Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11858919 HDAC1,2 inhibitors

Patent 11858919 was granted and assigned to Regenacy Pharmaceuticals on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Regenacy Pharmaceuticals

0

Current Assignee

Regenacy Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Charles Blum0

Ralph Mazitschek0

John H. Van Duzer0

Date of Patent

January 2, 2024

0

Patent Application Number

172784850

Date Filed

September 25, 2019

0

Patent Citations

US Patent 9421212 Selective HDAC1 and HDAC2 inhibitors

0

US Patent 7868205 Inhibitors of histone deacetylase

0

US Patent 8168658 Inhibitors of histone deacetylase

0

US Patent 8598168 Inhibitors of histone deacetylase

0

US Patent 9145412 Selective HDAC1 and HDAC2 inhibitors

0

US Patent 10774056 Substituted piperazines as selective HDAC1,2 inhibitors

0

Patent Primary Examiner

Shawquia Jackson

0

CPC Code

0

0

0

Patent abstract

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11858919 HDAC1,2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool